Trials / Completed
CompletedNCT02104427
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- GPCR Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG-0054 combined with G-CSF |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2014-04-04
- Last updated
- 2021-04-19
- Results posted
- 2017-12-13
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02104427. Inclusion in this directory is not an endorsement.